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Introduction 
Cardiovascular diseases (CVDs) are the leading causes of death in the world and also 
in Hungary. CVDs are a group of disorders of the heart and blood vessels, including e.g. 
ischemic heart diseases (IHDs). IHD is the most common type within the group of CVDs 
being responsible for approximately 46% of deaths caused by CVDs. IHD is a group of 
diseases that includes stable angina, unstable angina, myocardial infarction, and sudden 
cardiac death. The common feature of these diseases is reduced blood supply to the 
myocardium with deficit of oxygen and nutrients. It could be emphasized that in Hungary 
acute myocardial infarction (AMI) has the highest mortality rate among IHDs. AMI is mainly 
caused by a thrombotic occlusion of a coronary artery following the rupture of a vulnerable 
atherosclerotic plaque. The most effective therapy for reducing AMI injury is timely and 
effective myocardial reperfusion. However, the reperfusion therapy – that is essential to 
salvage myocardium - can itself induce further cardiomyocyte death termed reperfusion 
injury. Currently there is no effective therapy for reducing AMI-induced cellular damage and 
death, therefore development of new therapeutic approaches for limiting myocardial infarct 
size has a great clinical potential. 
Myocardial ischemia/reperfusion (I/R) injury is a phenomenon of cellular damage in 
the heart that is initiated during hypoxia and becomes exacerbated when oxygen delivery and 
tissue pH are restored. The exact pathomechanism of I/R has not been yet fully elucidated. 
The mechanisms contributing to the pathogenesis of I/R injury are multifactorial, complex 
and involve parallel regulation of cell death and cell survival processes. Two major forms of 
cellular death, apoptosis and necrosis can be observed in cardiomyocytes induced by I/R.  
Autophagy is a cell survival mechanism, a nonstop renewal process responsible for the 
degradation of damaged organelles and macromolecules. During I/R autophagy can also 
promote cell survival by generating reusable components to maintain function during 
nutrient-limited conditions.  
Currently there is no effective cytoprotective therapy for I/R injury. It is known, that 
the heart has a remarkable ability to adapt to I/R stress and the investigation of these 
cardioprotective mechanisms has been in the focus of intensive research in the last three 
decades. Preconditioning markedly improves the ability of the heart to withstand a long 
ischemic insult. Ischemic preconditioning (IPre) is a well-described adaptive response in 
which there is a brief exposure to I/R before prolonged ischemia. This approach has limited 
clinical relevance and failed to be translated to useful clinical treatments. However, 
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elucidation of the underlying mechanisms of IPre helped to develop numerous 
pharmacological agents mimicking cardioprotection induced by IPre. Several studies have 
shown that IPre leads to alteration of global gene expression, and microRNAs (miRNAss) has 
been recently recognized as fine-tuning posttranscriptional modulators of gene expression. 
Therefore the modulation of gene expression and protein levels with posttranscriptional 
regulation via miRs might lead to increased cell survival or more efficient adaptation for 
stress situations and can be an alternative and effective therapeutic way of induction of 
cardioprotection. Besides modulation of gene expression, in pharmacological preconditioning, 
application of natural molecules modulating cell signaling via cell membrane receptors could 
be able to induce cardioprotection. Moreover, it has been shown recently that extracellular 
matrix-derived macromolecules also contribute to cardioprotection. Implantation of injectable 
ECM hydrogel derived from decellularized myocardial tissue after AMI, decreased cardiac 
remodeling and preserved ejection fraction. Moreover, in the hearts of transgenic mice 
overexpressing the ECM component small leucine-rich proteoglycan, biglycan was shown to 
increase expression of several genes and proteins associated with cardioprotection .  
In this thesis, we aimed to investigate the potential pharmacological preconditioning 
effect of some macromolecules, i.e. biglycan and miRs against simulated 
ischemia/reperfusion (SI/R) injury in primary rat cardiomyocytes.  
Biglycan consists of an approximately 43 kDa core protein and two high-molecular 
weight glycosaminoglycan (GAG) side chains that can be either dermatan or chondroitin 
sulfate. The role of biglycan in the cardiovascular system is controversial. It was shown to be 
involved in the initiation of atherosclerosis and in heart failure. Conversely, the lack of 
biglycan has led to abnormal long-term cardiac remodeling and increased mortality in 
biglycan-knock out mice subjected to coronary occlusion. Our research group has previously 
demonstrated that exogenously administered biglycan could protect neonatal cardiac 
myocytes against SI/R injury. Although these findings suggest that biglycan exerts 
cardioprotective effects, the exact molecular mechanism behind this phenomenon has not yet 
been elucidated. Biglycan has been reported to bind to several cell membrane receptors 
including integrin receptors, growth factor receptors, Toll-like receptors (TLR) and scavenger 
A receptors in macrophages, however, the role of these receptors in biglycan-induced 
cardiocytoprotection has not been investigated.  
Growing evidence suggests that microRNAs (miRNAs) have an important role in 
various physiological and pathological processes in the heart including cardiac development, 
myocyte contractility and cellular response to different stress. MiRNAs are endogenously 
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expressed small – 21-25 nucleotides’ long –non-coding RNA molecules, encoded in almost 
all organisms from viruses to humans and act as powerful posttranscriptional regulators of 
gene expression and have a pivotal role in cardiovascular functions.  
Several studies demonstrated that the systemic use of chemically modified miRNA 
modulators (mimicking or inhibiting the miRNA function) has a great therapeutic potential in 
various disease states. Our research group has investigated the preconditioning-induced 
miRNAs expression profile in Langendorff-perfused rat hearts and suggested a set of 
therapeutically applicable miRNAs with potential cardioprotective features. In this present 
thesis we aimed to strengthen whether pharmacological modulation of selected 
preconditioning-associated miRNAs indeed protect primary neonatal cardiomyocytes against 
SI/R, thereby proving the causative role of these selected miRNAs in pharmacological 
preconditioning.  
Aims 
In the present thesis our aim was to investigate whether certain natural or modified 
macromolecules are able to protect the primary neonatal cardiomyocytes against simulated 
ischemia/reperfusion injury. 
A) Our fist aim was to investigate the potential cardiocytoprotective effect of the small 
leucine rich proteoglycan biglycan. 
Therefore we have assessed:  
 whether the core protein or the glycosaminoglycan side chains (dermatan 
sulfate or chondroitin sulfate) are responsible for the cardiocytoprotective 
effect of native biglycan 
 if the mechanism of action of biglycan involves Toll-like receptor 4 signaling, 
well-known cardioprotective mediators (e.g. nitric oxide, ERK, Protein kinase 
B), protection from oxidative stress, inhibition of cell death and induction of 
cell survival processes. 
B) Our second aim was to test whether the modulation of selected preconditioning-
associated miRNAs is able to protect cardiomyocytes against SI/R injury. 
Materials and methods 
All procedures used have been in accordance with the Directive 2010/63/EU of the 
European Parliament and were approved by the local animal ethics committee of the 
University of Szeged. 
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Characterization of the cytoprotective effect of biglycan 
In pilot experiments, we tested whether the core protein obtained by enzymatic 
removal of GAG chains from biglycan induces cytoprotection. Two days old cardiomyocyte 
cultures were treated with 0 - 100 nM native (glycanated) or deglycanated biglycan for 20 h, 
and were subjected to 150 min SI followed by 120 min simulated reperfusion. Following 
simulated reperfusion, the ratio of dead cells was determined by Trypan blue staining. The 
native and deglycanated biglycan treatments were maintained throughout SI/R. 
In order to further investigate which structural component is responsible for the 
cardiocytoprotective effect of biglycan, in a separate setup, cardiomyocytes were pretreated 
with 0-100 nM concentration of native biglycan, recombinant human biglycan core protein 
(rhBGNc) and the corresponding concentrations of dermatan sulfate or chondroitin sulfate for 
20 h followed by 240 min SI and 120 min simulated reperfusion. During SI, the cells were 
covered with hypoxic solution and kept in a multigas incubator set to 0.4% O2, 5% CO2, 
94.6% N2. At the same time, to determine the rate of cell death due to SI/R, cells grown on 
two removable strips of each Strip well plate were covered with a normoxic solution and kept 
in a standard CO2 incubator for 240 min followed by 120 min of simulated reperfusion. At the 
end of the reperfusion, cell viability was measured by calcein assay. In SI/R experiments, data 
obtained with various treatments were expressed as percentage of SI/R-induced cell death.  
To determine if biglycan treatment directly increases cell count in the absence of SI/R, 
in separate experiments, the effects of rhBGNc treatment were investigated on cell 
proliferation with 5’-bromo-2’-deoxyuridine (BrdU) incorporation assay as well as on 
viability in normoxic control cultures.  
To further strengthen the relevance of our findings we have subjected primary adult rat 
cardiomyocytes to 45 min simulated ischemia followed by 120 min simulated reperfusion. 
During SI/R the cells were treated with a vehicle or rhBGNc. SI/R was induced the same way 
as for primary neonatal cultures, however, since adult cells are more sensitive to SI/R-induced 
damage shorter duration of simulated ischemia (45 min) was applied. Cell viability was 
determined using calcein assay.  
To examine if the cytoprotective effect of rhBGNc includes modulation of necrotic or 
apoptotic cell death or autophagy, cell cultures were subjected to SI/R with or without 
treatment with 10 nM rhBGNc as described above and compared to normoxic controls. 
Necrosis was assessed by measurement of lactate dehydrogenase (LDH) release to the 
medium, while apoptosis was assessed by activated caspase-3 immunostaining (overall 
apoptosis) and by estimation of mitochondrial membrane potential with JC-1 staining 
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(intrinsic apoptosis). Autophagy was assessed by LC3 I/II immunocytochemistry and western 
blot analysis. 
To explore the mechanism of action of the biglycan core protein, first we tested if 
exogenously administered rhBGNc is capable to bind to cells. Cardiomyocyte cultures were 
treated with His6-tagged rhBGNc followed by detection of the His6-tag in the cellular fraction 
or supernatant using western blot.  
To further investigate whether TLR4 signaling is involved in the protective 
mechanism of rhBGNc, 10 nM rhBGNc was applied with or without the TLR4 signaling 
inhibitors, TAK-242 or Lipopolysaccharide from Rhodobacter Sphaeroides, LPS-RS for 20 h 
pretreatment and during SI/R, then viability was measured by calcein assay. 
 To explore the downstream mechanisms of rhBGNc and TLR4, cardiomyocytes were 
treated with 10 nM rhBGNc in the presence or absence of inhibitors of IRAK-1/4, 
MEK/ERK, JNK and p38 MAPKs.  
To further elucidate the possible downstream molecular mechanisms of biglycan core 
protein signaling, activation of well-known cardioprotective pathways, i.e. RISK and SAFE 
pathways were investigated in response to rhBGNc treatment. The alterations of 
phosphorylated or total Akt (Protein kinase B), ERK1/2 and Signal transducer and activator of 
transcription 3 (STAT3) proteins after 20 h rhBGNc treatment were determined by Western 
blot analysis. Activation of ERK was also assessed following 10 min, 1 h and 20 h of rhBGNc 
treatment. 
For assessment of the role of nitric oxide (NO) and oxidative stress in the protective 
effect of rhBGNc, cardiomyocytes were treated with 10 nM rhBGNc for 20 h, then NO 
content and superoxide production was measured. In separate experiments, cells were treated 
with 10 nM rhBGNc in the absence or presence of NO synthase inhibitor Nω-Nitro-L-arginine 
methyl ester hydrochloride (L-NAME) for 20 h followed by SI/R. Then viability was 
measured by calcein staining. Superoxide production was also measured in cells subjected to 
normoxia or SI/R with or without rhBGNc treatment. 
To investigate the potential effect of biglycan on oxidative stress, we set up a H2O2 
cytotoxicity protocol. In preliminary experiments the concentration of H2O2 inducing 
approximately 50% all death was determined (50 µM H2O2). Then one-day-old primary 
neonatal cardiomyocytes were treated with biglycan for 20 h followed by 50 µM H2O2 
treatment for 24 h during which appropriate biglycan treatments were maintained. At the end 
of the protocol, cell viability was measured by calcein assay.  
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Cytoprotective effect of selected preconditioning-associated miRNAs  
Prior to test the potential cytoprotective effect of miRNAs against SI/R, miRNAs 
showing altered expression in response to ischemic preconditioning were identified. Isolated 
Langendorff-perfused hearts were subjected to I/R with or without ischemic preconditioning 
and differential expression of miRNAs were determined by miRNA microarray. Based on the 
microarray results three miRNAs were chosen for further investigations in neonatal 
cardiomyocyte cultures and transfected before SI/R. Thus the effects of mimics of rno-miR-
139-5p and rno-miR-125b* and an antagonist of rno-miR-487b were tested on viability in 
neonatal cardiomyocytes subjected to SI/R.  
Results 
 Both native biglycan and deglycanated biglycan protects against SI/R-induced cell death 
We confirmed that treatment of cardiomyocytes with glycanated native biglycan 
attenuates SI/R-induced cell death in a dose-dependent manner. To test whether deglycanated 
biglycan obtained after enzymatic removal of GAG chains exerts cytoprotective effects, 
deglycanated biglycan was prepared by digesting native biglycan with Chondroitinase ABC. 
The deglycanated biglycan also exerted a similar dose-dependent attenuation of SI/R injury. 
These data suggest that the core protein plays an important role in the cardiocytoprotective 
effect of biglycan. 
The biglycan core protein rather than the GAG chains is responsible for the protective 
effect of biglycan 
To further investigate the role of the core protein and the GAG chains in the 
cardiocytoprotective effect of biglycan, a different approach was used to look separately at the 
effects of distinct structural components of biglycan. In this experimental setup, 
approximately 30% of the cells die due to SI/R.  
Native biglycan protected cardiomyocytes against SI/R injury in a dose-dependent 
manner. In order to confirm whether the core protein of biglycan is responsible for the 
observed cardioprotective effect, a recombinant human GAG-free core protein (rhBGNc) was 
used for treatments. 
SI/R-induced cell death was attenuated by rhBGNc in a dose-dependent manner 
showing a U-shaped curve. The 3 and 10 nM concentrations of rhBGNc decreased the cell 
death significantly compared to the vehicle group. To test the potential effects of GAG chains 
on SI/R injury, dermatan sulfate or chondroitin sulfate was applied in a dose range (0.105-
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10.5 µg/mL GAGs), corresponding to the biglycan concentrations applied in the previous 
experiments (1-100 nM). Neither concentrations of the dermatan sulfate influenced 
significantly the SI/R-induced cell death.  
Biglycan core protein protects primary adult cardiomyocytes from SI/R-induced cell death 
Since the prevalence of I/R injury is higher in adults, we have verified if the 
cytoprotective effect of rhBGNc can be demonstrated in adult cells as well. Therefore we 
have prepared adult rat cardiomyocyte cultures and tested whether rhBGNc is able to protect 
primary adult rat cardiomyocytes against SI/R-induced cell death. While 45 min simulated 
ischemia followed by 120 min simulated reperfusion significantly decreased the cell viability 
compared to normoxic controls, 30 nM rhBGNc significantly attenuated SI/R-induced cell 
death. 
Biglycan core protein does not increase cell proliferation 
In order to assess whether the biglycan core protein-dependent increase in viability 
after SI/R is due to direct cytoprotection or enhanced cell proliferation, we determined the 
effect of rhBGNc on cell viability under normoxic conditions as well as on cell proliferation 
assessed by BrdU incorporation. BrdU incorporation was not increased and cell viability was 
not affected significantly by biglycan core protein under normoxic conditions. These data 
suggest that the cytoprotective effect of rhBGNc is not due to increased cell proliferation.  
Biglycan core protein influences SI/R-induced necrosis and apoptosis 
Release of the cytoplasmic enzyme LDH into the culture medium is a characteristic 
sign of necrotic cell death. LDH activity of culture supernatants was significantly increased 
due to SI/R as compared to normoxic controls, however, LDH release from rhBGNc-treated 
cells subjected to SI/R was not significantly different from that of normoxic controls. 
To further characterize rhBGNc-related protection against SI/R-induced cell death, we 
studied the effect of rhBGNc on late events of apoptosis by performing cleaved caspase-3 
immunostaining. Caspase-3 activation was significantly increased in the SI/R group compared 
to normoxic controls, while rhBGNc significantly attenuated SI/R-induced elevation of 
cleaved caspase-3. These results suggest a potential antiapoptotic effect of rhBGNc.  
To reveal whether the protective effect of rhBGNc on SI/R subjected cells involves 
mitochondrial events, the changes in mitochondrial membrane potential were measured after 
SI/R by JC-1 staining. Cells subjected to SI/R had significantly decreased mitochondrial 
membrane potential compared to normoxic controls. The rhBGNc-treatment somewhat 
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improved mitochondrial membrane potential, as no significant difference in the red-to-green 
fluorescence was found when compared to the normoxic controls. However, based on these 
results, the contribution of mitochondrial apoptotic pathways to the antiapoptotic effect of 
rhBGNc during SI/R seems to be minor. 
Biglycan core protein influences autophagy 
  To investigate whether the cytoprotective effect of rhBGNc against SI/R involves 
modulation of autophagy, presence of autophagic vacuoles was detected using 
immunocytochemistry. Autophagy was present in the cells exposed to normoxic conditions 
which effect was attenuated under SI/R and enhanced back by the cytoprotective effect of 
biglycan. In parallel, immunoblotting showed decreased conversion of LC3 I to LC3 II (a 
marker of decreased autophagy) under SI/R, which was recovered to the normoxic levels 
under the effect of biglycan. 
Cytoprotection by biglycan core protein involves Toll-like receptor signaling  
In order to assess whether exogenously administered rhBGNc is associated to cells 
indicating possible receptor binding, cardiomyocyte cultures were treated with His6-tag 
labeled rhBGNc. Western blot analysis using an anti-His6-tag antibody demonstrated the 
presence of exogenously administered rhBGNc in both the cellular and supernatant fractions 
indicating that biglycan core protein binds to cardiomyocytes.  
To investigate the potential mechanisms of action of biglycan core protein, we tested if 
inhibition of TLR4 signaling interferes with the cytoprotective effect of rhBGNc against SI/R 
injury. The TLR4 signaling inhibitors TAK-242 and LPS-RS abolished the cytoprotective 
effect of rhBGNc, however, they did not affect cell death when administered alone.  
In order to confirm the involvement of TLR4 signaling in the cardiocytoprotective effect of 
rhBGNc, specific pharmacological inhibitors of IRAK-1/4, MEK/ERK, JNK, and p38 – well 
known downstream members of TLR4 signaling – were applied alone or in combination with 
rhBGNc on cardiomyocytes subjected to SI/R. RhBGNc significantly decreased SI/R-induced 
cell death observed in the vehicle group, however, the cytoprotective effect of rhBGNc was 
abolished in the presence of the inhibitors of IRAK-1/4, MEK/ERK, p38 MAPK and JNK, 
respectively. The inhibitors alone did not affect significantly the viability of the 
cardiomyocytes. These results suggest that TLR4 signaling is involved in the protective effect 
of rhBGNc. 
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 Biglycan core protein enhances Akt and ERK phosphorylation  
To further elucidate the possible downstream molecular mechanisms of biglycan core 
protein signaling, activation of well-known cardioprotective pathways – RISK and SAFE 
pathways – were investigated in response to 20 h of rhBGNc treatment. Western blot analysis 
showed that 20 h of rhBGNc treatment significantly enhances Akt phosphorylation without 
affecting phosphorylation of STAT3 or ERK1/2. Since ERK1/2 is also a component of TLR4 
signaling and known for its rapid phosphorylation/dephosphorylation kinetics, we have looked at 
ERK phosphorylation at earlier time points after rhBGNc treatment. Phosphorylation of ERK1 
was markedly increased after 10 min rhBGNc treatment, however, rhBGNc-induced ERK1 
phosphorylation was attenuated after 1 h, and was abolished after 20 h of treatment. 
Phosphorylation of ERK2 showed a similar tendency without reaching the level of statistical 
significance. 
NO is involved in the cytoprotective effect of biglycan core protein 
To assess the possible involvement of NO signaling in the cytoprotective effect of 
biglycan core protein, the NO content was measured in cardiomyocyte cultures after spin 
trapping. NO level of cardiomyocytes was elevated after 20 h of rhBGNc treatment. To 
confirm the causative role of NO signaling in the protective effect of biglycan core protein, in 
separate experiments, rhBGNc was applied in the presence or absence of the NO synthase 
inhibitor L-NAME. RhBGNc significantly decreased cell death compared to the untreated 
group, however, L-NAME abolished the cytoprotective effect of biglycan core protein.  
The biglycan core protein attenuates the SI/R-induced superoxide production. 
To investigate the effect of biglycan on superoxide level, cardiomyocyte cultures were 
treated with rhBGNc for 20 h, with or without SI/R injury and superoxide production was 
determined by DHE staining. RhBGNc had no effect on superoxide production in a stress free 
environment, however, it significantly attenuated the SI/R-induced increase in superoxide 
level.  
The native biglycan attenuates the H2O2-induced cytotoxicity. 
To assess the possible involvement of superoxide elimination in the cytoprotective 
effect of biglycan, we have set up an H2O2-induced cell death model. One day old cultures 
were treated with 0, 3, 10, or 30 nM biglycan for 20 hours followed by 50 µM H2O2 treatment 
for 24 h while the appropriate biglycan treatments were maintained. At the end of the 
protocol, cell viability was measured.  
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We found that H2O2 resulted in a marked loss of cells. Pretreatment with biglycan 
dose-dependently protected the cardiomyocytes and 30 nM biglycan significantly reduced the 
H2O2-induced cell death. These data suggest that biglycan might have a role in attenuation of 
oxidative stress in cardiac myocytes.  
Preconditioning-associated miRNA modulators protect primary neonatal cardiomyocytes 
from SI/R injury  
In the present thesis we aimed to demonstrate that modulation of the expression of 
preconditioning-associated miRNA with specific, exogenously administered, synthetic 
oligonucleotide modulators is able to protect cardiomyocytes from SI/R-induced cell death. 
Therefore, to validate the possible relationship between miRNAs and cardiocytoprotection, 
the preconditioning-associated rno-miR-139-5p as well as rno-miR-125b* mimick (agonist) 
and an inhibitor (antagonist) of rno-miR-487b were transfected into primary neonatal 
cardiomyocytes and the cells were then subjected to SI/R. The SI/R significantly decreased 
cell viability compared to the normoxic control. We found that the transfection of 
cardiomyocytes with any of the modulators of the three selected miRNA significantly 
decreased all death caused by SI/R. Therefore, these miRNAs can be used as potential 
therapeutic target molecules in the treatment of SI/R–induced cellular damage. 
Discussion and conclusion 
New findings 
 
1. The biglycan core protein protects cardiomyocytes against cell death induced SI/R, while 
the GAG side chains do not exert a protective effect. 
In the present study we have confirmed that biglycan attenuates cell death induced by 
SI/R in cardiomyocytes. In addition, we have demonstrated for the first time that the core 
protein of biglycan rather than the GAG chains of the molecule are responsible for the 
observed cytoprotection. 
2. The rhBGNc modulates the effect of SI/R upon necrosis, apoptosis and autophagy. 
We demonstrated that the LDH activity of culture supernatants (marker of necrotic cell 
death) was significantly increased due to SI/R as compared to normoxic controls, however, 
LDH release from rhBGNc-treated cells subjected to SI/R was not significantly different from 
that of normoxic controls. Caspase-3 activation (a marker of overall apoptosis) was 
significantly increased in the SI/R group compared to normoxic controls, while rhBGNc 
significantly attenuated SI/R-induced elevation of cleaved caspase-3. The rhBGNc treatment 
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somewhat improved mitochondrial membrane potential (marker of intrinsic apoptosis), but 
the contribution of mitochondrial apoptotic pathways seems to be minor in the antiapoptotic 
effect of rhBGNc during SI/R. The rhBGNc treatment recovered the SI/R-induced decrease 
autophagy to the normoxic level.  
3. Cytoprotection by biglycan core protein involves Toll-like receptor signaling. 
With the help of pharmacological inhibitors we have shown that the cytoprotective 
effect of biglycan core protein is mediated via activation of TLR4 signaling and involves the 
adaptor molecule IRAK-1/4 and its downstream targets, ERK, JNK and p38 MAP kinases.  
4. Biglycan core protein enhances Akt and ERK phosphorylation and NO production. 
The treatment of cardiomyocytes with rhBGNc resulted in increased Akt and ERK1 
phosphorylation and enhanced production of NO which plays a role in the 
cardiocytoprotective effect of biglycan core protein. 
5. Biglycan exerts antioxidant effects.  
The native biglycan attenuated the H2O2-induced cell death and rhBGNc significantly 
attenuated SI/R-induced increase in superoxide production. 
6. Modulation of selected preconditioning-associated miRNAs protect primary neonatal 
cardiomyocytes from SI/R injury. 
The mimics of rno-miR-139-5p and rno-miR-125b* and an inhibitor of rno-miR-487b were 
able to significantly decrease the cell death caused by SI/R.  
In conclusion, the core protein of biglycan mediates cytoprotection against SI/R injury 
in cardiomyocytes by modulating the effects of SI/R on necrosis, apoptosis, and autophagy. 
The molecular mechanism of action of biglycan core protein involves TLR4 signaling, 
activation of Akt, ERK, as well as JNK and p38MAP kinases and increased NO production. 
Biglycan is able to improve cell survival against H2O2 induced cell death and rhBGNc 
attenuates the SI/R-induced increase of superoxide level. These findings suggest an 
antioxidant role for biglycan, however, the mechanisms is still unclear. The novel 
cytoprotective effect of biglycan core protein may provide a basis for development of 
potential future therapeutic applications for the treatment of myocardial infarction as a tool for 
pharmacological preconditioning. Another way to elicit pharmacological preconditioning is 
the modulation of preconditioning-associated miRNA expression. The selected synthetic 
miRNA modulators protect the primary neonatal cardiomyocytes from SI/R injury. These 
15 
 
miRNAs serve as potential targets for modulation by specific miRNA mimics or inhibitors to 
achieve cardioprotection. In this present study we have demonstrated novel directions for 
pharmacological preconditioning to protect primary cardiomyocyte cultures from SI/R.  
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